Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lyell Immunopharma Inc (LYEL)

Lyell Immunopharma Inc (LYEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 548,945
  • Shares Outstanding, K 21,244
  • Annual Sales, $ 60 K
  • Annual Income, $ -342,990 K
  • EBIT $ -256 M
  • EBITDA $ -251 M
  • 60-Month Beta -0.14
  • Price/Sales 9,598.68
  • Price/Cash Flow N/A
  • Price/Book 1.42

Options Overview Details

View History
  • Implied Volatility 106.99% (-1.49%)
  • Historical Volatility 58.52%
  • IV Percentile 23%
  • IV Rank 6.19%
  • IV High 760.93% on 03/17/25
  • IV Low 63.82% on 04/17/25
  • Expected Move (DTE 6) 1.15 (4.44%)
  • Put/Call Vol Ratio 0.31
  • Today's Volume 21
  • Volume Avg (30-Day) 55
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 1,157
  • Open Int (30-Day) 537
  • Expected Range 24.69 to 26.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -2.14
  • Number of Estimates 2
  • High Estimate -1.94
  • Low Estimate -2.35
  • Prior Year -14.40
  • Growth Rate Est. (year over year) +85.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.07 +22.64%
on 02/09/26
27.89 -7.35%
on 01/22/26
+2.13 (+8.98%)
since 01/13/26
3-Month
16.77 +54.08%
on 11/14/25
45.00 -42.58%
on 12/22/25
+8.43 (+48.42%)
since 11/13/25
52-Week
7.65 +237.78%
on 06/02/25
45.00 -42.58%
on 12/22/25
+14.20 (+121.99%)
since 02/13/25

Most Recent Stories

More News
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma

PiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell...

LYEL : 25.84 (+1.81%)
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting 83% overall response and 61% complete...

LYEL : 25.84 (+1.81%)
Lyell Immunopharma: Q3 Earnings Snapshot

Lyell Immunopharma: Q3 Earnings Snapshot

LYEL : 25.84 (+1.81%)
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 

Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety profile...

LYEL : 25.84 (+1.81%)
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal...

LYEL : 25.84 (+1.81%)
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for...

LYEL : 25.84 (+1.81%)
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment...

LYEL : 25.84 (+1.81%)
Lyell Immunopharma Announces Participation in September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing next-generation...

LYEL : 25.84 (+1.81%)
Lyell Immunopharma: Q2 Earnings Snapshot

Lyell Immunopharma: Q2 Earnings Snapshot

LYEL : 25.84 (+1.81%)
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphoma Initiated the PiNACLE...

LYEL : 25.84 (+1.81%)

Business Summary

Lyell Immunopharma Inc. is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell Immunopharma Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 29.04
2nd Resistance Point 28.15
1st Resistance Point 26.99
Last Price 25.84
1st Support Level 24.94
2nd Support Level 24.05
3rd Support Level 22.89

See More

52-Week High 45.00
Fibonacci 61.8% 30.73
Fibonacci 50% 26.33
Last Price 25.84
Fibonacci 38.2% 21.92
52-Week Low 7.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar